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Abstract
Background—Information on cancer stage is critical for guiding treatment and assessing disease 
prognosis. The Percentage of unknown staged cancer cases varies considerably across state cancer 
registries; factors contributing to the variations in unknown stage have not been reported in the 
literature before. The purpose of this study was to examine whether these variations are influenced 
by demographic and clinical factors as well as type of reporting facilities.
Methods—Invasive colorectal, lung, female breast, and prostate cancers diagnosed in 2004–2007 
and staged (derived Summary Stage 2000) according to Collaborative Stage Version 1 were 
obtained from the North American Association of Central Cancer Registries (NAACCR); 47 
population-based cancer registries in the United States were included. Relative importance 
analysis was used to identify variables that were relatively important in predicting unknown stage. 
We used multiple linear regression to evaluate factors associated with percentage of unknown 
stage by cancer site using state central cancer registries as analytic units; potential outlier registries 
with high percentage of unstaged cases were identified using boxplots and standardized residuals.
Results—Overall, lung cancer had the highest percentage of unknown stage (8.3%) and prostate 
cancer had the largest variation of unknown stage among registries (0.6%–18.1%). The 
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percentages of neoplasm Not Otherwise Specified (NOS) histology, non-microscopically 
confirmation, and non-hospital reporting source were positively associated (p<0.05) with 
percentage of unknown stage for all studied cancer sites before adjustment. Variables that retained 
a positive association with unknown stage after adjusted for demographic variables, clinical 
variables, year of diagnosis, and type of reporting source were black race, metropolitan area < 1 
million population, histologies of neoplasm NOS or epithelial neoplasm NOS, diagnosis year 
2005, and non-hospital reporting source for colorectal cancer; metropolitan area < 1 million 
population, neoplasm NOS histology, and non-hospital reporting source for female breast; and 
diagnosis year 2005 and non-hospital reporting source for prostate. After adjustment, none of the 
predictors were significant for lung cancer. We observed one potential outlier registry each for 
colorectal, lung, and female cancers.
Conclusions—Factors associated with unknown stage differ by cancer site; however, type of 
reporting source is an important predictor of unknown stage for all cancers except lung after 
adjustment. Cancer registries with high percentage of unknown stage should be made aware of 
their data quality issue(s). As a result, these registries can investigate those factors and provide 
training to registrars to improve their cancer data quality.
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Cancer; Summary Stage; Collaborative Stage; Cancer Registry
Introduction
Information on cancer staging is essential for assessing the effectiveness of early detection, 
intervention, planning treatment, and predicting outcome. Formed in 1998, the Collaborative 
Staging (CS) Task Force,1 now known as the CS Governance Committee, developed the CS 
Data Collection System for use with cases diagnosed in 2004 and after to resolve the issue 
of discrepancies in staging guidelines and to provide a higher degree of compatibility among 
the three major cancer staging systems: American Joint Committee on Cancer (AJCC) 
staging,2 Surveillance, Epidemiology, and End Result (SEER) Summary Stage,3 and SEER 
Extent of Disease (EOD).3 An additional advantage of using CS is the reduction in unknown 
stage rates. A study using data in the CDC’s National Program of Cancer Registries (NPCR) 
Cancer Surveillance System (CSS) observed a decreased percentage of unknown SEER 
Summary Stage 2000 (SS2000) from 2001–2003 to 2004–2005.4
The percentage of unknown stage is a strong quality indicator of stage data as well as the 
quality of abstraction and availability of source data. The Data Assessment Workgroup of 
the North American Association of Central Cancer Registries (NAACCR) Data Use and 
Research Committee (DURC) found that the percentage of unknown stage cases varies 
substantially by cancer registry and cancer site.5 The common approach in handling 
unknown stage cancer cases in research is to exclude them from the statistical analysis; 
however, this could create biased results.6 To help registries to implement appropriate 
strategies to improve quality of stage data, it is important to identify and quantify factors 
associated with unknown stage. Unfortunately these studies are lacking in the literature. 
Previous studies on cancer stage primarily focused on finding factors associated with 
advanced stage only.7–11 The purposes of this study were to identify factors associated with 
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unknown stage cases at central registry level for colorectal, lung, female breast, and prostate 
cancer as well as to identify registries with unusual high percentages of unstaged cases.
Data and Methods
Data Source
Data from 47 United States (US) population-based cancer registries were obtained from the 
NAACCR Cancer in North America (CINA) Analytic file 1995–2007 data which included 
48 US state cancer registries (Maryland and Nevada were not included in this analytic file). 
Minnesota was excluded because the Rural/Urban 2003 Continuum code was not available. 
We included invasive colorectal (ICD-O-312 Topography: C18.0–C18.9, C19.9, C20.9), lung 
(C34.1–C34.9), female breast (C50.0–C50.9), and prostate cancer (C61.9) diagnosed in the 
years 2004 to 2007. Autopsy or death-certificate-only cases, lymphomas originating in the 
sites of interest, and cases with unknown Rural/Urban information were excluded from the 
analysis.
The outcome of interest was the percentage of cases with unknown SEER Summary Stage 
2000 (SS2000) derived from Collaborative Stage Version 1 (CSv1) at the central registry 
level. Independent variables were demographic (i.e., race, sex, age, and rural/urban 
residence) and clinical (i.e., histology, grade, and diagnostic confirmation) data, as well as 
year of diagnosis and type of reporting source. Residence regions were defined based on the 
2003 Rural/Urban Continuum codes12: county metropolitan areas with populations of one 
million or more, county metropolitan areas with populations of less than one million, and 
non-metropolitan areas. Histologies were categorized as: neoplasms, Not Otherwise 
Specified (NOS) (ICD-O-313 morphology 8000–8005), epithelial neoplasms NOS (8010–
8046), adenocarcinoma NOS (8140), and specified histologies. The type of reporting source 
was grouped into two categories: hospital and non-hospital facilities. Beginning with cases 
diagnosed in 2006, two new categories, radiation treatment centers/medical oncology centers 
(hospital-affiliated or independent) and other hospital outpatient units/surgery centers, were 
introduced as types of reporting sources in NAACCR records.14–15 The hospital group 
included: hospital inpatient, radiation treatment centers/medical oncology centers, and 
hospital outpatient units/surgery centers. The non-hospital facilities included: physician’s 
office, nursing home/hospice, and laboratory only.
Statistical Analysis
The relative importance of variables16 was adopted to describe the contribution of each 
variable in explaining the variance of the outcome. In detail, independent variables were 
sequentially added to the linear regression models, from which the increase in R square was 
recorded for each variable. We permuted the order of variables to be added in the linear 
models. The relative importance of the variables is defined as the average increase in R 
square from the permutation for each variable. Variable with high relative importance index 
indicates that the predictor is relatively important in predicting the percentage of unknown 
stage, which was treated as a continuous variable ranging variously by cancer site.
Hsieh et al. Page 3
J Registry Manag. Author manuscript; available in PMC 2018 March 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Multiple linear regression was used to evaluate the relationship between the predictors and 
the percentage of cases with unknown stage for selected cancer sites and the regression 
models were run separately for each cancer site. The covariate was the percentage of patients 
falling into each particular subgroup of a predictor at central registry level. Therefore a 
predictor with k categories forms k-1 covariates. To identify registries with unusually high 
percentages of unknown stage, we used the upper whisker of the boxplots of the unadjusted 
percentages and the standardized residuals generated from the multiple linear regression 
model that adjusted for important factors. The upper whisker of the boxplots is defined as 
the largest data point of unknown stage percentage within the boundary of following 
formula: Third quartile + 1.5× (Third quartile- First quartile). Any registries with 
standardized residuals of unknown stage percentage higher than the upper bound of 95% 
conference interval (CI) were considered to have unusually high percentage of unstaged 
cases. The statistical significant level was set at 0.05. All analyses were carried out using 
SAS® version 9.2 (SAS Institute, Cary, NC).
Results
Lung cancer had the highest percentage of unknown derived SS2000 (8.3%), followed by 
colorectal cancer (7.2%) and prostate cancer (6.6%); female breast cancer had the lowest 
percentage of unstaged cases (3.5%) for all cases combined (Table 1). At the registry level, 
the ranges of percentages of unknown stage varied substantially for all studied cancer sites, 
particularly for prostate cancer with a range from 0.6%–18.1% (Table 1). The three most 
important predictors based on relative importance analysis for colorectal cancer were 
histology type, type of reporting source, and tumor grade; for lung cancer, type of reporting 
source, diagnostic confirmation, and age; for female breast cancer, type of reporting source, 
histology type, and diagnostic confirmation; and for prostate cancer, tumor grade, type of 
reporting source, and urban/rural area (Figure 1).
Colorectal Cancer
Registries with higher percentages of patients residing in non-metropolitan areas or with 
higher percentages of moderately differentiated tumor grade had lower percentages of 
unknown stage (Table 2), whereas registries with higher percentages of neoplasms NOS 
histology, higher percentages of unknown diagnostic confirmation, or higher percentages of 
non-hospital cases had higher percentages of unknown stage in the univariate analysis. After 
adjustment for all predictors, the percentages of cases with unknown stage differed 
significantly by race, rural/urban residence, histology type, diagnostic confirmation, 
diagnosis year and type of reporting source. The difference was particularly strong for 
histology type. Compared with specified histology, a 1% increase of neoplasms NOS or a 
1% increase of epithelial neoplasms NOS was related to an average of 2.7% or 3.7% 
increase in unstaged rate after controlling for other predictors (Table 2).
Lung Cancer
When other predictors were not controlled, older age groups were related to lower 
percentages of unknown stage than those aged less than 50 years old (Table 2), and registries 
with higher percentages of neoplasms NOS or unknown microscopic confirmation or non-
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hospital reporting sources were associated with higher percentages of unknown stage. 
However, after adjusting for other predictors, no predictors were significantly associated 
with unknown stage.
Female Breast Cancer
The percentages of cases with histologies of neoplasm NOS or unknown diagnostic 
confirmation or non-hospital reporting source had positive associations with unknown stage 
in univariate analysis. This is most striking for unknown diagnostic confirmation. Compared 
with microscopically confirmed cases, a 1% increase of unknown diagnostic confirmation 
rate related to about an average of 6% increase in the percentage of unknown stage (Table 
2). After adjusting for other predictors, the percentage of patients residing in metropolitan 
areas with populations less than one million, the percentage coded to neoplasms NOS, and 
the percentage abstracted at non-hospital sources were positively associated with unknown 
stage. Compared to specified histology, a 1% increase of neoplasms NOS was related to an 
average of 3.2% increase in unstaged rate after other covariates were controlled.
Prostate Cancer
Although tumor grade yielded the highest importance index in the variable relative 
importance test (Figure 1), no statistically significant differences resulted when the 
percentages of well-differentiated cases were compared with other grade groups in the 
model that was not adjusting for other predictors (Table 2). However, the F-test showed that 
tumor grade was statistically significantly associated with percentage of unknown stage (p-
value=0.014). We further examined the association using unknown grade as baseline and 
found that grades of moderately and poorly differentiated had negative associations with the 
percentage of unknown stage (coefficients −0.731 and −0.579, respectively). After 
adjustment, registries with higher percentages of cases diagnosed in 2005 or higher 
percentage of cases reported by non-hospital reporting sources were more likely to have a 
higher percentage of unstaged prostate cancer cases.
Identifying registries with high unstaged rate
Before adjusting for all important predictors, we identified two registries as outliers with 
high unstaged rates (above upper whisker) for colorectal cancer, one for lung, six for breast 
and six for prostate cancer (Table 1). After adjustment, we found that only two registries had 
unusually high percentages of unknown stage (outside the upper bound of 95% CI), one for 
both colorectal and female breast cancers and one for lung cancer.
Discussion
The percentage of unknown stage varied by registry and by cancer site. Overall, female 
breast cancer had the lowest percentage of unknown stage cases among the four sites. 
Neoplasm NOS, unknown diagnostic confirmation, and non-hospital reporting source were 
positively associated with high percentages of unknown stage for all four cancer sites. 
Although race has been associated with advanced stage for colorectal, female breast, and 
prostate cancer,7–11 it was significantly associated with unknown stage only for colorectal 
cancer after controlling for other predictors in our study. Diagnosis year alone was 
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associated with unknown stage only in 2005 for colorectal and prostate cancer after 
adjustment. Colorectal cancer without microscopic diagnostic confirmation had a lower 
percentage of unstaged cases in the linear regression model (a 1% increase in the percentage 
of cases lacking diagnostic confirmation rate reduced the rate of unknown stage by about 4% 
after controlling for other covariates). The reasons for this unexpected result could be that 
diagnostic confirmation interacts with other predictors and/or does not fit in an ordinary 
linear regression model. Some predictors with high relative importance indexes were not 
significantly associated with unknown stage after adjustment because they are not 
significantly different from other predictors in terms of relative importance. Although breast 
and prostate cancers had higher numbers of registries with high percentage of unstaged 
cases; after adjustment, only one registry retained a high percentage of unknown stage, and 
that was for breast cancer only.
We did not observe a consistent decrease in the percentage of unknown stage over time as 
anticipated, except for lung cancer. However, the decrease in the unknown stage percentage 
for lung cancer diagnosed in 2005, 2006, or 2007 was not significantly different from cases 
diagnosed in 2004. For colorectal, female breast, and prostate cancers the changes in the 
percentage of unknown stage varied by diagnosis year. The failure to observe a declining 
trend in unknown stage could be due to a short observation time period and/or improperly 
interpreted or unclear CS coding guidelines. This study included only four years of data, 
from diagnosis year 2004 to 2007. During this time period, several updates and changes 
occurred in the Collaborative Staging coding schema. Although several training and 
education webinars and workshops were conducted before and after the CS Data Collection 
System was implemented, some of the coding guidelines might not have clearly explained 
the use of coding rules such as code none versus unknown.
As expected, state central registries with a higher percentage of cases diagnosed in non-
hospital facilities yielded a higher percentage of unknown stage than registries having higher 
percentage of cases diagnosed in hospitals before and after adjustment, except for lung 
cancer after adjustment. This could reflect lack of information in non-hospital charts and 
underscore the need for proper and complete data collection from non-hospital facilities.
The multiple imputation method has been commonly used in dealing with missing values.17 
Eisemann et al. showed it is a useful technique for imputing missing values for tumor stage 
except for cancer sites with high percentages of missing stage information.18 Therefore, it is 
critical that cancer registries reduce the unknown stage percentage as well as unknown 
percentages for other important variables to generate more valid results when using registry 
data.
This study has several strengths. First, it included 47 of the 50 US state cancer registries; 
therefore, the results are generalizable of the whole US. Second, data were collected and 
coded uniformly based on CS and NAACCR rules, ensuring that coding schemes for 
variables used in this study were the same across registries. Third, we used central registry 
level data as an analysis unit, instead of the individual cancer case level; this can identify 
issues occurring at individual registries and can also identify potential outlier registries.
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Despite these strengths, there are a few limitations to this study. The registries’ experience of 
coding SEER Extent of Disease (EOD)3 was not taken into account in the analysis. Coding 
rules for tumor size, tumor extension and lymph node involvement in SEER EOD were 
adapted and modified in the CS system. Registries that collected SEER EOD for cases 
diagnosed before 2004 may have been more likely to accept the concept of coding CS data 
items. Another limitation is that class of case (NAACCR item 160)14 information was not 
available in our study. Non-analytic cases (Class of case codes 3–9),14 which include cases 
not diagnosed and/or treated at reporting facility, provide very limited information on CS-
related information; therefore, registries with high percentages of non-analytic cases may 
increase the unstaged percentage.
In summary, our study has shown that for colorectal, lung, female breast, and prostate 
cancers the important predictors of unknown percentage of derived SEER Summary Stage 
2000 at the univariate level include histologic type, diagnostic confirmation, and type of 
reporting source. The relative importance of these factors, however, varies by site. For 
cancer registries having a higher percentage of unknown stage, further investigation of 
factors that caused higher unknown stage percentage is needed. Population-based cancer 
registry data are a valuable source for cancer research; any effort to reduce the percentage of 
unstaged cases will improve the quality of cancer data and produce more reliable cancer 
research results. A future study on changes in unknown staged rates over time is needed as 
more data become available.
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Figure 1. 
Variable relative Importance by cancer site
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Table 1
Measures of central tendency and dispersion on unknown derived summary stage 2000 by cancer site from 47 
United States population-based cancer registries 2004–2007
Colorectal Lung Female Breast Prostate
Mean for all cases combined 7.17% (N=552,242) 8.25% (N=761,739) 3.51% (N=746,887) 6.59% (N=781,923)
Based on individual registry
 Mean 6.40% 7.30% 3.11% 5.34%
 25–75% Percentile (IQR1) 4.61%–7.27% 4.95%–9.03% 1.56%–3.27% 2.59%–6.44%
 Minimum 2.40% 2.44% 0.98% 0.61%
 Median 5.48% 6.55% 2.29% 3.78%
 Maximum 18.80% 18.68% 13.68% 18.06%
 
2
 Upper Whisker 11.25% 15.16% 5.83% 12.23%
 
3
 Lower Whisker 2.40% 2.44% 0.98% 0.61%
 Number of registry outside of upper whisker 2 1 6 6
1
IQR: Interquartile range
2Upper Whisker: extends to largest data point within the boundary of Q3 + 1.5* (Q3−Q1)
3
Lower Whisker: extends to smallest data point within the boundary of Q1 − 1.5* (Q3−Q1)
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